Healthcare
Petlife Pharmaceuticals, Inc.(PTLF)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +17.5%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Petlife Pharmaceuticals, Inc. (PTLF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +17.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +17.5%, free cash flow -110.0% with operating margin 0.0% and ROIC 3410.5%. Stock Foundry combines PTLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2012 was reported on Jul 23, 2012, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +17.5%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2012 Jul 23, 2012 | โ | +0.0% | +0.0% | +0.0% |
2012 Apr 23, 2012 | โ | +0.0% | +0.0% | +0.0% |
2012 Jan 18, 2012 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTLF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PTLF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PTLF and SPY.
Company Overview
Petlife Pharmaceuticals, Inc.
Other OTC
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.
- Leadership
- Sebastian Serrell-Watts
- IPO Date
- May 14, 2008
- Employees
- 1
- Street Address
- 8033 Sunset Boulevard
- Mailing
- Los Angeles, CA, 90046
- Region
- Los Angeles, CA, US
- Reporting Currency
- USD
- Investor Line
- 424-216-6807
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +17.5%
- Free Cash Flow
- -110.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 1007.6%
- ROIC
- 3410.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.